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LETTERS TO THE EDITOR
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sRegarding “Optimal statin type and dosage for
vascular patients”
Paraskevas et al1 are claiming that rosuvastatin or atorvastatin
is the optimal statin at a dose of 20 mg/d for vascular patients.
Epidemiologic studies showed that a low level of high-density
lipoprotein cholesterol (HDL-C; 1.0 mmol/L or 40 mg/dL),
independent of low-density lipoprotein cholesterol (LDL-C), is a
marker of cardiovascular risk.2 Despite the known efficacy of the
various statins to increase HDL-C, the interindividual response is
rather high and unpredictable. Therefore, the optimal HDL-C–
elevating statin in a particular patient cannot be predicted.
The authors state that statin-induced adverse events may be
dose-related, which is substantiated by large trials. However, it is
well known that these studies underestimate side effects, partly
because the exclusion criteria avoid to a large extent possible drug
interactions. Especially side effects, such as mild myopathies, have
not been specifically questioned and documented. No data from
comparative trial investigating muscular side effects are available
yet.
In 1000 patients admitted to our lipid unit because of side
effects, the prevalence of myopathy exactly reflected the frequency
that the respective statins were prescribed at that time (Table).3 A
creatine kinase increase (5-fold) on statin monotherapy was
extremely rare (16 of 1111 patients). Therefore, there is no evi-
dence that atorvastatin is associated with the highest and fluvastatin
with the lowest risk of adverse events.
The assumption that milder side effects of certain statins are
counterbalanced by their lower efficacy is not evidence-based.
With the option of a weekly dosing of a long half-life statin for
statin-intolerant patients, the authors contradict their own asser-
tion that only the most potent statins at20mg/d are appropriate
for vascular patients. Furthermore, statin-intolerant patients who
do not tolerate any lipid-lowering agent, even on alternate-day
dosing, should therefore undergo LDL apheresis, according to the
respective national guidelines.
In our unit in 50% of patients with clinically symptomatic
and proven atherosclerosis, other statins than rosuvastatin and
atorvastatin are effective to achieve target values according to the
guidelines. A 40% decrease in LDL-C has been described as
being necessary to induce regression of atherosclerosis.4 A long-
term lesion stabilization achieved by LDL-lowering to target val-
ues may be sufficient. What is the clinical proof concerning the
cardiovascular event rate for the 40% LDL-lowering? Interindi-
vidual response to various statins varies considerably, not allowing
preferential recommendations.
Moreover, statins have pleiotropic effects, independent of
changes in serum cholesterol, not considered by Paraskevas et al,1
including improving endothelial function, exerting anti-inflamma-
Table. The prevalence of myopathy exactly reflected the
frequency that the respective statin was prescribeda
Statin Patients no. (%) Myopathies (%)
Patient total 1111
Simvastatin 400 (36.01) 34.80
Atorvastatin 396 (35.64) 37.20
Fluvastatin 156 (14.04) 14.00
Pravastatin 111 (9.99) 11.80
Lovastatin 41 (3.69) 0.70
Rosuvastatin 7 (0.63) 1.50o
paUnpublished data.
928ory actions, and stabilizing atherosclerotic plaques.5 Furthermore,
o statement on combination treatment, which would also allow
chieving the goal with other statins, is given.
In some patients, extremely elevated lipoprotein(a) (100
g/dL), cigarette smoking, or other risk factors despite normal
ipids, are the key pathogenetic mechanisms for the development
f vascular disease. These patients do not fit into the therapeutic
ecommendations at all.
We agree with a key statement that adherence to statin therapy
s the central problem to be addressed in this group of patients.
owever, we do not believe that this simple statin type and dose
ecommendation for vascular disease patients is justified at present.
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Berent and Sinzinger1 raise many, mostly questionable points.
irst, regarding their comment that a low level of high-density
ipoprotein cholesterol (HDL-C) is a marker of cardiovascular risk
ndependent of low-density lipoprotein cholesterol (LDL-C) lev-
ls, a recent systematic review and meta-regression analysis of 108
tudies, including 299,310 participants, showed that by increasing
DL-C levels, there is no reduction in the risk of coronary heart
isease events, coronary heart disease deaths, or total deaths.2 This
eta-analysis concluded that a reduction in LDL-C levels should
e the primary goal for lipid-modifying interventions.2
Second, the response of patients varies with all drugs; we
uggested statin types and dosages that are more likely to achieve
uideline targets.3 There will also always be variations in statin use.
urely, Berent and Sinzinger do not advocate a random choice of
tatin types and dosages.
Third, they question the statement that statin-induced “my-
pathy” is dose-related and mention that “especially side effects,
uch as mild myopathies, have not been specifically questioned and
ocumented.”1 The authors seem not to be aware of a study
ublished last year, the Study of the Effectiveness of Additional
eductions in Cholesterol and Homocysteine (SEARCH). This
tudy, comprising 12,064 participants, showed that the incidence
f myopathy was 30-fold greater in patients taking 80 mg com-
ared with 20 mg of simvastatin.4
